ArticleFrontiers in oncology2017
Plasma Lipidomic Signature of Rectal Adenocarcinoma Reveals Potential Biomarkers.
Article in Frontiers in oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Metabolomics and Biomarker Discovery.Advances in experimental medicine and biology · 2026Review
- Serum metabolomics reveals distinctive signature of cancer staging in oral squamous cell carcinoma.BMC oral health · 2025Article
- Tumor Microenvironment, Inflammation, and Inflammatory Prognostic Indices in Diffuse Large B-Cell Lymphomas: A Narrative Review.International journal of molecular sciences · 2025Review
- Multi-omics staging of locally advanced rectal cancer predicts treatment response: a pilot study.La Radiologia medica · 2024Article
- Disturbed Plasma Lipidomic Profiles in Females with Diffuse Large B-Cell Lymphoma: A Pilot Study.Cancers · 2023Article
- Aberrant circulating tumor DNA methylation and exosomal microRNA biomarkers for early detection of colorectal cancer.Molecular biology reports · 2023Review
- Synthesis of ether lipids: natural compounds and analogues.Beilstein journal of organic chemistry · 2023Review
- Association of levels of metabolites with the safe margin of rectal cancer surgery: a metabolomics study.BMC cancer · 2022Article
- Serum untargeted lipidomics by UHPLC-ESI-HRMS aids the biomarker discovery of colorectal adenoma.BMC cancer · 2022Article
- Plasma Lipid Profile Reveals Plasmalogens as Potential Biomarkers for Colon Cancer Screening.Metabolites · 2020Article
- Roles of endogenous ether lipids and associated PUFAs in the regulation of ion channels and their relevance for disease.Journal of lipid research · 2020Review
- Selected Oxidative Stress Markers in Colorectal Cancer Patients in Relation to Primary Tumor Location-A Preliminary Research.Medicina (Kaunas, Lithuania) · 2020Article
- Mass spectrometry imaging to detect lipid biomarkers and disease signatures in cancer.Cancer reports (Hoboken, N.J.) · 2019Review
- Curbing Lipids: Impacts ON Cancer and Viral Infection.International journal of molecular sciences · 2019Review
- Biomarkers in Colorectal Cancer: The Role of Translational Proteomics Research.Frontiers in oncology · 2019Review
- Reduced Plasma Levels of Very-Long-Chain Dicarboxylic Acid 28:4 in Italian and Brazilian Colorectal Cancer Patient Cohorts.Metabolites · 2018Article
- Rapid discrimination of pediatric brain tumors by mass spectrometry imaging.Journal of neuro-oncology · 2018Article
- Ionizing radiation exposure: hazards, prevention, and biomarker screening.Environmental science and pollution research international · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRectal adenocarcinoma (RAC) is a common malignant tumor of the digestive tract and survival is highly dependent upon stage of disease at diagnosis. Lipidomic strategy can be used to identify potential biomarkers for establishing early diagnosis or therapeutic programs for RAC.
objectiveTo evaluate the lipoperoxidation biomarkers and lipidomic signature in the plasma of patients with RAC (
methodsLipoperoxidation was evaluated based on malondialdehyde (MDA) and F
resultsThe most abundant ions identified in the RAC patients were those of protonated phosphatidylcholine and phosphatidylethanolamine. It was found that a lisophosphatidylcholine (LPC) plasmalogen containing palmitoleic acid [LPC (P-16:1)], with highest variable importance projection score, showed a tendency to be lower in the cancer patients. A reduction of
conclusionThis study shows that the reduction in plasma levels of LPC plasmalogens associated with an increase in MDA levels may indicate increased oxidative stress in these patients and identify the metabolite LPC (P-16:1) as a putatively novel lipid signature for RAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.